Prosecution Insights
Last updated: April 19, 2026
Application No. 18/447,142

Methods to Produce Heterogeneous Polyethylene Granules

Final Rejection §Other
Filed
Aug 09, 2023
Examiner
DIAMOND, ALAN D
Art Unit
3991
Tech Center
3900
Assignee
ExxonMobil
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
79%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
137 granted / 192 resolved
+11.4% vs TC avg
Moderate +8% lift
Without
With
+7.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
21 currently pending
Career history
213
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
22.9%
-17.1% vs TC avg
§102
6.0%
-34.0% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 192 resolved cases

Office Action

§Other
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Reissue Applications For reissue applications filed on or after September 16, 2012, all references to 35 U.S.C. 251 and 37 CFR 1.172, 1.175, and 3.73 are to the current provisions. This application, filed August 9, 2023, is a reissue of U.S. Patent 11,492,428 (hereafter the '428 patent), which issued from U.S. application Serial No. 16/449,257 (the ‘257 application) with claims 1-24 on November 8, 2022. Objections and Rejections Overcome The objection to claims 10 and 11, and the rejection of claims 1-24 under 35 USC 112(b), have been overcome by Applicant’s amendment of the claims. Non-Compliant Amendment The amendment filed 10/07/2025 is improper. The amendment does not comply with 37 CFR 1.173 which sets forth the manner of making amendments in reissue applications. While the improper amendment has been entered and considered, a compliant amendment is required with Applicant’s next response. An amendment filed after final rejection that fails to comply with 37 CFR 1.173 may not be entered. All amendment changes must be made relative to the patent to be reissued, not relative to a previous submitted amendment. Pursuant to 37 CFR 1.173(d), any such changes which are made to the specification, including the claims, must be shown by employing the following markings: (1) The matter to be omitted by reissue must be enclosed in brackets, i.e., single brackets; and (2) The matter to be added by reissue must be underlined. The non-compliance issues are as follows: Claims 4 and 25 use double bracketing rather than single bracketing to delete subject matter. Claim 17 of the amendment has changed “Al 2 O3” at col. 34, line 64 of the ‘428 patent to “Al2O3” without using single bracketing and underlining. Reissue Applications The reissue oath/declaration filed 04/05/2024 is defective (see 37 CFR 1.175 and MPEP § 1414) because of the following: The reissue declaration is defective since the error it seeks to correct is one that may NOT be corrected by reissue. Applicant “seeks to submit an originally signed declaration from Inventor Mamo to correct the record.” However, Inventor Mamo was properly listed as an inventor during the prosecution of the original patent, albeit by a substitute statement in lieu of an originally signed oath/declaration. MPEP §1402(II) limits inventorship error to misjoinder of inventors. See 37 CFR §1.175, MPEP §§1412.04(Il) and 1414. A new reissue declaration with an acceptable error statement that supports the instant reissue application is required. An example of an acceptable error statement is as follows: “In claim 1, at col. 34, lines 2-3, ‘the first monomers and the second monomers’ raise an antecedent basis issue, i.e., a 35 USC 112(b) issue, in the claim.” Claims 1-24 are rejected as being based upon a defective reissue declaration under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175. The nature of the defect(s) in the reissue declaration is set forth in the discussion above in this Office action. Response to Arguments Applicant's arguments filed 10/07/2025 have been fully considered but they are not persuasive. Applicant argues the following on p. 6 of the Remarks: In response to the Notice to File Missing Parts of Reissue Application mailed on 8 February 2024, Applicant ExxonMobil Chemical Patents Inc. filed a Reissue Application Declaration by the Assignee (“2024 Declaration’) on 5 April 2024. The 2024 Declaration identifies Assignee as Applicant and does not include an oath or declaration from Inventor Mamo, and so it is unclear what defects remain to be corrected. In addition, Applicant filed an ADS on 5 April 2024 identifying Assignee as the Applicant. It is believed that the 2024 Declaration and ADS filed on 5 April 2024 address the Notice of 8 Feb 2024, and Applicant respectfully requests removal of the objection. Applicant’s argument is unpersuasive. The Notice to File Missing Parts is not the basis for the reissue declaration filed 04/05/2025 being defective. Rather, as noted above, the reissue declaration is defective because the error identified in the error statement cannot be corrected by reissue. In particular, the fact that, in the ‘257 application, inventor Malmo was listed in a Substitute Statement rather than in an originally signed oath/declaration, is not an error correctable by reissue. As noted above, a new reissue declaration with a proper error statement is required. Duty to Disclose Applicant is reminded of the continuing obligation under 37 CFR 1.178(b), to timely apprise the Office of any prior or concurrent proceed-ing in which Patent No. 11,492,428 is or was involved. These proceedings would include interferences, reissues, reexaminations, and litigation. Applicant is further reminded of the continuing obligation under 37 CFR 1.56, to timely apprise the Office of any information which is mate-rial to patentability of the claims under consideration in this reissue appli-cation. These obligations rest with each individual associated with the filing and prosecution of this application for reissue. See also MPEP §§ 1404, 1442.01 and 1442.04. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALAN D DIAMOND whose telephone number is (571)272-1338. The examiner can normally be reached Monday through Thursday 5:30 am to 3:00 pm, and Fridays from 5:30 am to 9:30 am. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Patricia Engle can be reached on 571-272-6660. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Signed: /ALAN D DIAMOND/Patent Reexamination Specialist Central Reexamination Unit 3991 Conferees: /JOSEPH R KOSACK/ /Patricia L Engle/Patent Reexamination Specialist SPRS, Art Unit 3991 Central Reexamination Unit 3991
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Jul 08, 2025
Non-Final Rejection — §Other
Oct 07, 2025
Response Filed
Oct 15, 2025
Final Rejection — §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE50811
Rapid Imaging Systems and Methods for Facilitating Rapid Radiation Therapies
2y 5m to grant Granted Mar 10, 2026
Patent RE50805
SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
2y 5m to grant Granted Feb 24, 2026
Patent RE50799
JAK1 SELECTIVE INHIBITORS AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent RE50790
INK COMPOSITION, INK JET RECORDING METHOD, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE AND PLANOGRAPHIC PRINTING PLATE
2y 5m to grant Granted Feb 10, 2026
Patent RE50776
INHIBITORS OF CYCLIN-DEPENDENT KINASES
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
79%
With Interview (+7.6%)
2y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 192 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month